These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16956543)

  • 1. [Pandoraea pulmonicola isolation in patients with cystic fibrosis].
    Pérez de Ayala-Balzola A; Buendía-Moreno B; Girón-Moreno RM; López-Brea M
    Enferm Infecc Microbiol Clin; 2006; 24(7):473-4. PubMed ID: 16956543
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of amplified ribosomal DNA restriction analysis for identification of Ralstonia and Pandoraea species: interest in determination of the respiratory bacterial flora in patients with cystic fibrosis.
    Segonds C; Paute S; Chabanon G
    J Clin Microbiol; 2003 Jul; 41(7):3415-8. PubMed ID: 12843108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and identification of Pandoraea spp. From bronchoalveolar lavage of cystic fibrosis patients in Iran.
    Tabatabaei M; Dastbarsar M; Moslehi MA
    Ital J Pediatr; 2019 Sep; 45(1):118. PubMed ID: 31477148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis.
    Talbot NP; Flight WG
    Paediatr Respir Rev; 2016 Aug; 20 Suppl():27-9. PubMed ID: 27374622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays.
    Coenye T; Liu L; Vandamme P; LiPuma JJ
    J Clin Microbiol; 2001 Dec; 39(12):4452-5. PubMed ID: 11724860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the gyrB gene for the identification of Pandoraea species.
    Coenye T; LiPuma JJ
    FEMS Microbiol Lett; 2002 Feb; 208(1):15-9. PubMed ID: 11934487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-genome analysis of
    Bayjanov JR; Ekkelenkamp MB; Rogers MR; Cantón R; Benaissa-Trouw BJ; Díez-Aguilar M; Tunney M; Fluit AC
    Future Microbiol; 2019 Nov; 14():1357-1367. PubMed ID: 31762328
    [No Abstract]   [Full Text] [Related]  

  • 8. A new approach to the treatment of Xanthomonas maltophilia respiratory infection in a patient with cystic fibrosis.
    Taylor RF; Gaya H; Empey DW
    Respir Med; 1998 Feb; 92(2):363-4. PubMed ID: 9616541
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis.
    Talmaciu I; Varlotta L; Mortensen J; Schidlow DV
    Pediatr Pulmonol; 2000 Jul; 30(1):10-5. PubMed ID: 10862157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemic spread of Pandoraea pulmonicola in a cystic fibrosis center.
    Degand N; Lotte R; Decondé Le Butor C; Segonds C; Thouverez M; Ferroni A; Vallier C; Mély L; Carrère J
    BMC Infect Dis; 2015 Dec; 15():583. PubMed ID: 26705696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients.
    Jørgensen IM; Johansen HK; Frederiksen B; Pressler T; Hansen A; Vandamme P; Høiby N; Koch C
    Pediatr Pulmonol; 2003 Nov; 36(5):439-46. PubMed ID: 14520728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and management of unusual pathogens in cystic fibrosis.
    Elborn JS
    J R Soc Med; 2008 Jul; 101 Suppl 1(Suppl 1):S2-5. PubMed ID: 18607011
    [No Abstract]   [Full Text] [Related]  

  • 13. Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness.
    Johnson LN; Han JY; Moskowitz SM; Burns JL; Qin X; Englund JA
    Pediatr Infect Dis J; 2004 Sep; 23(9):881-2. PubMed ID: 15361734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumonia due to Pandoraea Apista after evacuation of traumatic intracranial hematomas:a case report and literature review.
    Lin C; Luo N; Xu Q; Zhang J; Cai M; Zheng G; Yang P
    BMC Infect Dis; 2019 Oct; 19(1):869. PubMed ID: 31640582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the Aarhus centre in Denmark.
    Gade SS; Nørskov-Lauritsen N; Ridderberg W
    J Med Microbiol; 2017 May; 66(5):686-689. PubMed ID: 28481740
    [No Abstract]   [Full Text] [Related]  

  • 16. Pandoraea apista isolated from a patient with cystic fibrosis: problems associated with laboratory identification.
    Moore JE; Reid A; Millar BC; Jiru X; Mccaughan J; Goldsmith CE; Collins J; Murphy PG; Elborn JS
    Br J Biomed Sci; 2002; 59(3):164-6. PubMed ID: 12371061
    [No Abstract]   [Full Text] [Related]  

  • 17. Update on antibiotics for infection control in cystic fibrosis.
    Kirkby S; Novak K; McCoy K
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):967-80. PubMed ID: 19803706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled antibiotics in cystic fibrosis: what's new?
    Hewer SL
    J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S19-24. PubMed ID: 22688362
    [No Abstract]   [Full Text] [Related]  

  • 20. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
    De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
    J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.